Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Company profile
Website
CEO
Mark E. Pruzanski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Intercept Group Inc
SEC CIK
Corporate docs
IRS number
582237359
Latest filings (excl ownership)
424B3
Prospectus supplement
30 Nov 10
EFFECT
Notice of effectiveness
24 Nov 10
S-4
Registration of securities issued in business combination transactions
26 Oct 10
15-12G
Securities registration termination
8 Nov 04
DEFA14A
Additional proxy soliciting materials
29 Oct 04
425
Business combination disclosure
20 Oct 04
ARS
2003 FY
Annual report to shareholders
15 Oct 04
8-K
Other Events
12 Oct 04
DEFM14A
Proxy related to merger
12 Oct 04
Latest ownership filings
No filings